Stock Events

Stock Events

Benitec Biopharma 

€0.18
0
-€0-0% Tuesday 20:00

Statistics

Day High
-
Day Low
-
52W High
0.18
52W Low
0.18
Volume
-
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q4 2025
Next
-0.23
-0.22
-0.2
-0.19
Expected EPS
-0.2328975
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BJ93.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.72B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Benitec's gene-silencing technologies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.42B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a direct competitor in the RNA-based therapeutic space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap9.12B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, competing in the same gene-silencing niche.
Sarepta Therapeutics
SRPT
Mkt Cap2.22B
Sarepta Therapeutics is involved in genetic modulation, including RNA-targeted therapies, positioning it as a competitor in genetic disease treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disease treatments, overlapping with Benitec's target market.
Sangamo Therapeutics
SGMO
Mkt Cap104.07M
Sangamo Therapeutics works on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the broader genetic treatment market.
CRISPR Therapeutics
CRSP
Mkt Cap4.92B
CRISPR Therapeutics is engaged in gene editing, a different but competing approach to treating genetic diseases compared to Benitec's gene-silencing.
Editas Medicine
EDIT
Mkt Cap287.74M
Editas Medicine operates in the gene editing space, specifically CRISPR, offering alternative genetic disease treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics is another key player in CRISPR-based gene editing, providing competitive technologies for genetic disease treatment.

About

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Show more...
CEO
Dr. Jerel A. Banks M.D., Ph.D.
Employees
16
Country
United States
ISIN
US08205P2092

Listings

MU
DE
BJ93.MU
STU
DE
BJ93.STU
XNAS
US
BNTC
BOATS
BOATS
BNTC.BOATS

0 Comments

Share your thoughts

FAQ

What is Benitec Biopharma stock price today?▼
The current price of BJ93.STU is €0.18 EUR — it has decreased by -0% in the past 24 hours. Watch Benitec Biopharma stock price performance more closely on the chart.
What is Benitec Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Benitec Biopharma stocks are traded under the ticker BJ93.STU.
Is Benitec Biopharma stock price growing?▼
BJ93.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Benitec Biopharma has showed a +0% increase.
When is the next Benitec Biopharma earnings date?▼
Benitec Biopharma is going to release the next earnings report on May 18, 2026.
What were Benitec Biopharma earnings last quarter?▼
BJ93.STU earnings for the last quarter are -0.22 EUR per share, whereas the estimation was -0.19 EUR resulting in a -16.42% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Benitec Biopharma have?▼
As of April 16, 2026, the company has 16 employees.
In which sector is Benitec Biopharma located?▼
Benitec Biopharma operates in the Health & Wellness sector.
When did Benitec Biopharma complete a stock split?▼
Benitec Biopharma has not had any recent stock splits.
Where is Benitec Biopharma headquartered?▼
Benitec Biopharma is headquartered in Hayward, United States.